-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT)

SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the securities laws. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control hyperglycemia.

If you would like more information about Corcept Therapeutics Incorporated's misconduct, click here.

Corcept Therapeutics Incorporated (CORT) is Being Investigated for Illicit Sales Practices

On December 8, 2021, Corcept disclosed that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney's Office for the District of New Jersey (the 'NJ USAO') pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPPA) seeking information relating to the sale and promotion of Korlym, Corcept's relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym." The Company further disclosed that "[t]he NJ USAO has informed Corcept that it is investigating whether any criminal or civil violations by Corcept occurred in connection with the matters referenced in the subpoena."

On this news, Corcept's stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

Corcept Therapeutics Incorporated (CORT) shareholders have legal options. If you own shares of Corcept Therapeutics Incorporated, contact us to learn more about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Corcept Therapeutics Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:CORT

Release Summary
Corcept Therapeutics Incorporated (CORT) is Being Investigated for Illicit Sales Practices
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Ryde Group Ltd Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Ryde Group Ltd (NYSE: RYDE) securities between March 6, 2024 and September 11, 2024, inclusive (the "Class Period"). RYDE’s claimed “vision is to become a 'Super mobility app' where multiple mobility tools can be accessed and function seamlessly out of a single app, offering ultimate convenience and reliabili...

Investor Alert: Robbins LLP Informs Investors of the Dick's Sporting Goods, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The complaint alleges that defendants misled investors regarding Dick's growth, profitability and integration of recently acquired Foot Locker....

Investor Alert: Robbins LLP Informs Investors of the Beta Bionics Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The complaint alleges that defendants misled investors regarding the viability and efficacy of the Company's iLet Bionic Pancreas insulin pump....
Back to Newsroom